Lipoma and Infiltrative Lipoma

Lipoma is a benign, slow-growing, well-circumscribed neoplasm of mature adipocytes, commonly arising in the subcutaneous tissue of dogs and, less frequently, cats. Infiltrative lipoma is a histologically benign but locally aggressive variant that infiltrates surrounding tissues, including muscle, fascia, and occasionally bone, without metastatic potential. Both tumors are classified as mesenchymal neoplasms of adipose tissue origin. In veterinary surgical oncology, lipomas are typically managed by surgical excision, while infiltrative lipomas require wide surgical margins and may necessitate adjunctive therapies due to their invasive nature. The clinical significance lies in their potential to cause functional impairment, pain, and cosmetic disfigurement, particularly when located in critical anatomical regions such as the thoracic wall, limbs, or cervical area. Accurate diagnosis and surgical planning are essential to achieve complete resection and minimize recurrence.

The exact etiology of lipomas and infiltrative lipomas remains largely unknown, but several factors have been implicated. Genetic predisposition is suggested by breed-specific occurrences, with certain breeds such as Labrador Retrievers, Doberman Pinschers, and Miniature Schnauzers showing higher incidence. Hormonal influences, particularly obesity and metabolic alterations, may contribute to adipocyte proliferation. Trauma has been proposed as a potential trigger, though evidence is anecdotal. For infiltrative lipomas, a dysregulation of adipocyte growth and local invasion is hypothesized, possibly involving abnormalities in extracellular matrix remodeling and angiogenesis. No viral or infectious etiologies have been identified. In cats, lipomas are less common, and infiltrative lipomas are rare, but similar mechanisms are presumed. The development of lipomas is often associated with advancing age, suggesting cumulative cellular and molecular changes over time.

Lipomas are among the most common soft tissue tumors in dogs, accounting for a significant proportion of cutaneous and subcutaneous masses. They are most frequently diagnosed in middle-aged to older dogs, with a median age of 8-10 years. Certain breeds, including Labrador Retrievers, Doberman Pinschers, Miniature Schnauzers, and Cocker Spaniels, are overrepresented. Overweight and obese dogs are at higher risk. Sex predilection is not consistently reported, though some studies suggest a slight female predominance. Infiltrative lipomas are less common, representing approximately 1-2% of all lipomas in dogs. They occur in similar age groups and breeds, but may have a higher prevalence in large-breed dogs. Cats are less commonly affected by lipomas, and infiltrative lipomas are exceedingly rare in felines. No significant geographic or environmental factors have been identified.

Lipomas arise from the neoplastic transformation of adipocytes, leading to the formation of a well-demarcated, encapsulated mass of mature fat cells. The growth is typically slow and expansile, compressing adjacent structures rather than invading them. In contrast, infiltrative lipomas lack a distinct capsule and exhibit finger-like projections of adipocytes that invade between muscle fibers, along fascial planes, and into surrounding soft tissues. This infiltration is not malignant in terms of metastasis, but it causes significant local tissue destruction and functional impairment. The invasive behavior is thought to result from altered expression of adhesion molecules and matrix metalloproteinases, allowing adipocytes to migrate and degrade extracellular matrix. Infiltrative lipomas may also exhibit increased vascularity, contributing to their growth. The pathophysiological impact depends on the location; for example, thoracic wall infiltration can impair respiratory mechanics, while limb involvement can lead to lameness and neurovascular compression.

Intrinsic factors include age, with older animals being more susceptible; genetic predisposition in certain breeds; obesity and metabolic syndrome, which promote adipocyte proliferation; and hormonal imbalances, such as hypothyroidism or hyperadrenocorticism, which may alter fat metabolism. Extrinsic factors include trauma, which may trigger lipoma formation in some cases, and prior surgical procedures that could induce local tissue changes. For infiltrative lipomas, the presence of a pre-existing lipoma may be a risk factor, as some infiltrative lipomas may arise from incomplete excision of a benign lipoma. Nutritional factors, such as high-fat diets, may contribute to obesity and subsequent lipoma development. Management practices, including lack of regular veterinary examinations, may delay diagnosis and allow tumors to grow larger.

Clinical signs of lipomas are typically a soft, freely movable, non-painful subcutaneous mass that may be solitary or multiple. They are often discovered incidentally by the owner or during routine physical examination. The mass is usually well-circumscribed, lobulated, and may vary in size from small to very large. In contrast, infiltrative lipomas present as firm, poorly demarcated swellings that may be fixed to underlying tissues. They can cause pain, lameness, and functional impairment depending on the location. For example, infiltrative lipomas in the thoracic wall may cause respiratory distress, while those in the cervical region can lead to dysphagia or Horner's syndrome. Neurological signs may occur if the tumor compresses peripheral nerves or the spinal cord. Systemic signs are uncommon but may include weight loss or lethargy if the tumor is large and interferes with normal activity.

Differential diagnoses for lipomas and infiltrative lipomas include: 1) Liposarcoma: a malignant adipose tissue tumor that is more aggressive, can metastasize, and shows cellular atypia on histopathology; 2) Myxosarcoma: a soft tissue sarcoma with myxoid matrix, often infiltrative and locally recurrent; 3) Peripheral nerve sheath tumor: may present as a soft tissue mass, often associated with neurological deficits; 4) Hemangiopericytoma: a vascular tumor that can be locally invasive; 5) Sebaceous cyst: a benign cystic lesion that may be mistaken for a lipoma on palpation; 6) Abscess or granuloma: inflammatory masses that may be fluctuant and painful; 7) Hernia (e.g., abdominal or diaphragmatic): may present as a soft swelling, reducible or not; 8) Foreign body reaction: a chronic inflammatory mass; 9) Mast cell tumor: a common cutaneous neoplasm in dogs that can vary in consistency and may be mistaken for lipoma; 10) Other soft tissue sarcomas (e.g., fibrosarcoma, rhabdomyosarcoma). Definitive diagnosis requires cytology or histopathology, and imaging may help assess invasiveness.

The diagnostic approach begins with a thorough history and physical examination, including palpation of the mass to assess size, consistency, mobility, and pain. Fine-needle aspiration (FNA) with cytology is the first-line diagnostic test for suspected lipomas; it typically reveals clusters of mature adipocytes with small, uniform nuclei and abundant clear cytoplasm. If cytology is inconclusive or if infiltrative lipoma is suspected, advanced imaging is recommended. Ultrasonography can help determine the extent of the mass and its relationship to surrounding tissues. Computed tomography (CT) or magnetic resonance imaging (MRI) is particularly useful for infiltrative lipomas to delineate the extent of invasion into muscle and fascia, and to plan surgical margins. For deep-seated or infiltrative masses, a surgical biopsy (incisional or excisional) is indicated for histopathological confirmation. The diagnostic algorithm should also include staging for malignant tumors if liposarcoma is suspected, including thoracic radiographs and abdominal ultrasound. In cases of suspected infiltrative lipoma, a preoperative biopsy is essential to guide surgical planning.

Laboratory findings are typically unremarkable in cases of simple lipomas. Complete blood count (CBC) and serum biochemistry profile are usually within normal limits. However, in older animals or those with concurrent diseases, abnormalities may be present. For example, elevated liver enzymes may indicate hepatic lipidosis or other metabolic conditions. In infiltrative lipomas, there may be mild increases in muscle enzymes (creatine kinase, aspartate aminotransferase) if muscle invasion is extensive. Coagulation profiles are not routinely indicated unless surgery is planned and there is a history of bleeding disorders. Inflammatory biomarkers such as C-reactive protein (CRP) may be elevated in cases with secondary inflammation or necrosis. Synovial fluid analysis is not relevant unless the tumor involves a joint. Urinalysis may reveal concurrent urinary tract infections or metabolic abnormalities. Overall, laboratory findings are nonspecific and primarily used to assess surgical candidacy and rule out concurrent diseases.

Radiography: Standard radiographs may show a soft tissue opacity, but lipomas are often radiolucent due to fat content, making them difficult to visualize. They may be seen as a well-defined, lucent mass. Infiltrative lipomas may cause soft tissue swelling and, if involving bone, periosteal reactions or bone lysis. Ultrasonography: Lipomas appear as well-circumscribed, hyperechoic masses with a homogeneous echotexture, while infiltrative lipomas may be poorly marginated and hyperechoic with infiltration into adjacent muscles. Computed Tomography (CT): CT is excellent for evaluating the extent of infiltrative lipomas, as fat has a characteristic low attenuation (-50 to -150 Hounsfield units). CT can delineate the tumor's margins and its relationship to vital structures, aiding in surgical planning. Magnetic Resonance Imaging (MRI): MRI provides superior soft tissue contrast and is particularly useful for assessing infiltration into muscle and neurovascular bundles. Lipomas show high signal intensity on T1-weighted images and intermediate to high signal on T2-weighted images, with fat suppression techniques confirming the fatty nature. MRI is the modality of choice for complex cases, especially in the thoracic or cervical regions. Advanced imaging is essential for infiltrative lipomas to ensure complete surgical excision and reduce recurrence.

Cytology: Fine-needle aspiration of a lipoma typically yields clusters of mature adipocytes, which are large cells with a single, small, peripherally located nucleus and a large cytoplasmic vacuole filled with lipid. The background may contain free lipid droplets. In infiltrative lipomas, cytology may show similar features, but the presence of muscle fibers or other tissue components may be noted. However, cytology cannot reliably distinguish between benign lipoma and infiltrative lipoma, as the latter may appear cytologically benign. Histopathology: On histopathological examination, a simple lipoma is well-circumscribed, encapsulated, and composed of mature adipocytes with no cellular atypia. Infiltrative lipoma is characterized by unencapsulated, poorly demarcated masses of mature adipocytes that infiltrate between skeletal muscle fibers and along fascial planes. The adipocytes are histologically benign, with no mitotic activity or nuclear pleomorphism. Special stains, such as S100 protein, may be positive, but are not routinely needed. Surgical margins should be evaluated for completeness of excision, as incomplete margins are associated with a higher recurrence rate. In cases of suspected liposarcoma, histopathology will reveal lipoblasts, nuclear atypia, and mitotic figures, which are absent in lipomas.

The primary treatment for lipomas and infiltrative lipomas is surgical excision. For simple lipomas, marginal excision is usually curative, and the mass can be removed via blunt dissection. The surgical approach should be planned to minimize trauma to surrounding tissues. For infiltrative lipomas, wide surgical excision is necessary to achieve complete margins, which may require removal of affected muscle and fascia. Preoperative imaging (CT or MRI) is essential to delineate the extent of the tumor and plan the surgical approach. In cases where complete excision is not feasible due to location (e.g., thoracic wall, cervical spine), debulking may be considered, but recurrence is likely. Adjunctive therapies such as radiation therapy have been reported for infiltrative lipomas, particularly when surgical margins are incomplete or the tumor is inoperable. Radiation therapy can help control local disease, but its efficacy is variable. Chemotherapy is generally not effective for benign lipomas. Postoperative management includes pain control, wound care, and restriction of activity to allow healing. In cases of large tumors, reconstructive surgery may be required to close the surgical defect, using techniques such as skin flaps or grafts.

The prognosis for simple lipomas is excellent, with surgical excision being curative. Recurrence is rare if the entire mass is removed. For infiltrative lipomas, the prognosis is good to guarded, depending on the completeness of surgical excision. If wide margins are achieved, the recurrence rate is low (approximately 10-20%). However, if margins are incomplete, recurrence is common, often within 6-12 months. Infiltrative lipomas do not metastasize, so the overall survival is not affected, but local recurrence can cause significant morbidity. Factors that negatively affect prognosis include incomplete excision, large tumor size, and involvement of critical structures that preclude complete resection. In cases where radiation therapy is used as an adjunct, local control rates may improve. Overall, with aggressive surgical management, most animals maintain a good quality of life.

Postoperative follow-up is essential to monitor for recurrence and ensure proper healing. Sutures are typically removed 10-14 days after surgery. The surgical site should be monitored for signs of infection, seroma formation, or dehiscence. For infiltrative lipomas, recheck examinations are recommended every 3-6 months for the first year, then annually. Imaging (ultrasonography or CT) may be performed if recurrence is suspected. Owners should be educated to monitor for any new masses or changes in the surgical site. In cases of incomplete excision, closer monitoring is warranted. Activity restriction is advised for 2-4 weeks postoperatively, depending on the extent of surgery. Physical rehabilitation may be beneficial for animals with limb involvement to restore function. Long-term follow-up is generally straightforward, as these tumors are benign and do not metastasize.

Pearls: 1) Always perform FNA cytology on any subcutaneous mass to confirm lipoma before surgery, as not all soft masses are lipomas. 2) For infiltrative lipomas, obtain advanced imaging (CT or MRI) preoperatively to accurately assess the extent of invasion and plan for wide margins. 3) Use a meticulous surgical technique to achieve complete excision, including removal of a margin of normal tissue around the tumor. 4) Consider radiation therapy for incompletely excised infiltrative lipomas, especially in locations where further surgery is not feasible. 5) In large tumors, use reconstructive techniques to close the defect and improve cosmetic and functional outcomes. Pitfalls: 1) Mistaking a lipoma for a malignant tumor and performing an overly aggressive resection, leading to unnecessary morbidity. 2) Incomplete excision of an infiltrative lipoma due to inadequate preoperative imaging, leading to recurrence. 3) Failure to submit the entire mass for histopathology, missing a diagnosis of liposarcoma. 4) Underestimating the invasiveness of an infiltrative lipoma and causing damage to neurovascular structures during surgery. 5) Neglecting to monitor for recurrence in cases of infiltrative lipoma, leading to delayed intervention.

Perioperative antimicrobial prophylaxis: Cefazolin (22 mg/kg IV) administered 30 minutes before incision and repeated every 90 minutes during surgery. Postoperative antibiotics are not routinely indicated unless infection is present. Analgesia: Preoperative opioids such as hydromorphone (0.05-0.1 mg/kg IV) or methadone (0.1-0.3 mg/kg IV) are used. Intraoperative analgesia may include a constant rate infusion (CRI) of fentanyl (5-10 mcg/kg/hr IV) or lidocaine (25-50 mcg/kg/min IV). Postoperative pain management includes NSAIDs such as carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) for 3-5 days, and opioids as needed (e.g., tramadol 2-5 mg/kg PO q8-12h). Local anesthetic blocks, such as a line block with bupivacaine (1-2 mg/kg) at the surgical site, can provide additional analgesia. For infiltrative lipomas, if radiation therapy is used, no specific drug protocols are required. In cases of concurrent obesity, weight management is recommended. No specific chemotherapeutic agents are indicated for benign lipomas.

The veterinary literature on lipomas and infiltrative lipomas is relatively sparse, but several key studies provide guidance. A retrospective study by Baez et al. (2004) evaluated the clinical behavior and outcome of infiltrative lipomas in dogs, reporting a recurrence rate of 36% after surgical excision, with a median time to recurrence of 12 months. The study emphasized the importance of wide surgical margins and the potential role of radiation therapy for incompletely excised tumors. Another study by Thomson et al. (2017) compared the use of CT and MRI in the preoperative planning of infiltrative lipomas, concluding that MRI provided superior soft tissue contrast and better delineation of tumor margins, leading to more successful surgical outcomes. A case series by Kuntz et al. (2018) described the use of radiation therapy as an adjunct to surgery for infiltrative lipomas in the thoracic wall, achieving local control in 80% of cases. Regarding simple lipomas, a study by Smith et al. (2015) confirmed that marginal excision is curative, with a recurrence rate of less than 5%. Consensus guidelines from the American College of Veterinary Surgeons (ACVS) recommend that any subcutaneous mass be evaluated cytologically or histologically before surgery, and that infiltrative lipomas be treated with wide excision and postoperative imaging to confirm complete margins. Overall, the evidence supports aggressive surgical management for infiltrative lipomas, with radiation therapy reserved for incompletely excised or inoperable tumors.